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Abstract
In recent years, a strong focus has been put on the need to assure early coagulation support in order to prevent and treat 
coagulopathy in patients with severe trauma, and to improve survival. Aggressive plasma administration with high plasma/
red blood cells ratio is increasingly used worldwide. However, plasma transfusion is associated with increased risks of multiple 
organ dysfunction syndrome (MODS), adult respiratory distress syndrome (ARDS) and infection, which may prolong hospital 
stay and the need for artificial ventilation. Moreover, in the majority of European hospitals plasma cannot be immediately 
available and therefore it has been reported a significant delay in coagulation support. This has lead to the proposal of using 
clotting factors as an alternative to plasma. However, strong evidence to define the best strategy is still missing, and the only 
published protocols are Institution-specific, thus depending on the local organization and the available resources. The Italian 
Trauma Centers Network (TUN) recently developed a treatment protocol aiming at shortening the interval before the onset 
of coagulation support and at reducing the use of plasma. We present this protocol-Early Coagulation Support (ECS) Protocol 
- and discuss its rationale. Its implications for the trauma-team workflow and hospital organization are also addressed. The 
ECS protocol must be considered as an integrated part of a comprehensive Damage Control Strategy. The impact of the ECS 
Protocol on blood products consumption, trauma mortality and morbidity as well as its financial aspects, will be strictly 
monitored by the TUN hospitals. 
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Background
Haemorrhage is the principal cause of death in the first few hours 
following severe injury. Coagulopathy is a frequent complication 
of haemorrhage and may occur in up to 25% of patients, even 
before hospital admission [1]. In recent years, international 
guidelines [2] that aim at preventing and treating trauma-
induced coagulopathy (TIC), have been developed. However, 
due to the heterogeneous availability of haemocomponents 
and clotting factors in different countries and to the lack of 
sound data in the literature, there is not a widely agreed clinical 
strategy yet. Moreover, due to the aging population in western 
countries, elderly people with cardiovascular comorbidities and 
on antiplatelets agents or oral anticoagulants are increasingly 
represented. Therefore, a comprehensive protocol to treat the 
bleeding patients should also include strategies to quickly 
reverse the effect of these drugs.
Any strategy should rapidly tackle acute traumatic coagulo-
pathy through the early replacement of clotting factors. 
Haemostasis is critically dependent on fibrinogen as a substrate 
for clot formation. Fibrinogen is the single factor which is 
more and earlier affected in case of TIC. Many bleeding trauma 
patients with TIC present with a depletion of fibrinogen below 
levels currently recommended for therapeutic supplementation 
[2]. In a recent study, hypotension, increasing shock severity 
(as measured by the base deficit) and high degree of injury 
(ISS ≥25), were all associated with a reduction in fibrinogen 
levels [3]. Fibrinogen depletion is associated with poor 
outcomes and survival improves with the amounts of fibrinogen 
administered [4]. Plasma has traditionally been used as a source 
of fibrinogen. However, until few years ago plasma transfusion 
was not recommended in absence of a prolongation of PT or 
INR or fibrinogen decrease to less than 1.5 gr/L. More recently, 
retrospective evidence from both military [5] and civilian 
[6] practice suggested improved outcomes in patients with 
massive bleeding after the adoption of a massive-transfusion 
protocol (MTP), including the early administration of high-
dose plasma therapy. Although the first reports based on 
the military experience suggested a 1:1 plasma/packed red 
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blood cells (PRBCs) ratio, more recent data, supported by 
thromboelastometry, have shown that a lower rate (i.e., 1:2) 
may be preferable [7]. There are several limitations on the use 
of plasma to prevent and treat TIC. Both Fresh Frozen Plasma 
(FFP) and pathogen-inactivated plasma (industrial purified 
plasma) need to be group matched, thawed and warmed 
before administration. Therefore, unless pre-thawed plasma 
is available, plasma transfusion cannot be started at the same 
time as universal PRBCs. A delay of 93’ has been reported, 
[8] possibly explaining why the targeted plasma/RBCs ratio 
is reached only a few hours after starting treatment. During 
this interval fibrinogen level is likely to be lower than desired.
Plasma transfusion has also been associated with an 
increased risk of post injury MODS, ARDS and infections. 
These complications increase with the volume of transfused 
plasma [9]. The risk of transfusion related acute lung injury 
(TRALI) has been greatly reduced by avoiding the use of the 
plasma of women with pregnancy history [10]. In Italy the 
recent introduction of pathogen-inactivated plasma enabled 
to further minimize the risks of TRALI and virtually eliminate 
the risks of transmission of infective diseases. Although these 
measures are effective in reducing some of the adverse effects 
of plasma transfusions, recent data [11] show that in patients 
who require less than 6 Units of PRBCs, the complications 
related to plasma transfusion may overcome the benefits.
The balance between a rapid intervention to treat or prevent 
TIC and the risk related to unnecessary transfusion of plasma, is 
difficult to achieve. The use of coagulation factor concentrates 
have been proposed as the strategy to reduce and even avoid 
plasma transfusion in patients with significant bleeding. In 
the Austrian guidelines [12] fibrinogen concentrate is the 
first-line treatment. Two retrospective studies comparing 
data from Austrian Trauma Centres with the German Trauma 
(TR-DGU) registry, reported a significant reduction in platelet 
transfusion and a limited decrease in blood transfusion for 
bleeding patients treated with fibrinogen concentrate and 
prothrombin complex concentrate (PCC) who did not receive 
FFP during initial resuscitation [13,14]. Early coagulation 
monitoring with ROTEM was used to guide the administration 
of coagulation factors, starting immediately after patient 
admission. However, these results have not been confirmed 
by prospective controlled studies.
Although very appealing, the “plasma-free” strategy 
proposed by Schöchl [13] may not be easily adopted by 
Italian Trauma Centres as it requires thromboelastometry 
monitoring to be started straight on patient’s admission 
and only few Italian hospitals can adhere to this requirement 
at the moment. Moreover it may imply the use of a rather 
high amount of fibrinogen with considerable related costs. 
Fibrinogen availability might also turn out to be problematic as 
fibrinogen is not commercially available in Italy and hospitals 
are supplied with limited amount on the base of a national 
drugs agency (AIFA) authorization.
The Steering Committee of the Italian Trauma Update 
Network has recently developed a comprehensive treating 
protocol (Early Coagulation Support – ECS) to improve and 
homogenize the early treatment of trauma patients with 
significant bleeding and at high risk of massive transfusion. 
Compatibility with the resources currently available in the 
average Italian Trauma Centre is a key point of its rationale. 
Besides supporting coagulation and shorten the “time–to-treat” 
to effectively reduce the bleeding, the other main objective 
of the protocol is to limit the use of plasma in patients who 
are not likely to need it, in order to reduce plasma-related 
adverse effects.
Methods
The ECS protocol was developed by a multidisciplinary group 
of Anaesthetists, Haematologists, Surgeons and Intensive 
Care physicians involved in trauma care on daily basis. The 
Trauma Update Research Network (TUN) is an informal 
association of Italian Trauma Centres that jointly support and 
promote education and researches in Trauma Care sharing 
data and treatment strategies aimed to improve patients 
outcome. The ECS protocol is based on the available data 
from the current literature (as of August 2012). It is tailored 
on the current organization of the Italian Trauma Centres 
involved in the TUN, accounting for their limited financial and 
human resources. The TUN panel acknowledges the potential 
advantages of rapid (Point of Care) diagnostic tools to quickly 
identify coagulopathy and guide transfusion management as 
suggested by the European Guidelines [2]. However, the ECS 
protocol has been conceived to be feasible even when rapid 
diagnostic tools are not available, aiming to be a standard 
sustainable by all Institutions. The ECS protocol is presented 
in Table 1 and Table 2.
Results and Discussion
Based on the results of the Crash 2 study [15], the early 
administration of Tranexamic Acid (TA) to all patients with 
ongoing bleeding or at risk of significant bleeding is now 
standard care for the Trauma Centres of the TUN. According 
to the protocol, TA must be initiated on patient’s admission 
after the collection of a blood sample for laboratory tests, 
cross matching and basal clotting profile. TA must be initiated 
within the first 3 hours after trauma. If for any reason, a patient 
has not received TA within this deadline, TA administration is 
not recommended. Initial administration of TA complies with 
the Crash 2 study protocol: initial dose of 1gr, followed by a 
continuous infusion of the same dose of TA. If the viscoelastic 
monitoring allows to exclude ongoing fibrinolysis, further 
treatment may be avoided and the continuous TA infusion 
stopped.
The number of patients on antiplatelet or anticoagulation 
therapies is increasing. A retrospective cohort study of Trauma 
Centres, that submitted data to the National Trauma Databank 
(NTDB) from 2002 to 2007, demonstrated an increase in vitamin 
K antagonists (VKA) use in the general trauma population 
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from 2.3% in 2002 to 4% (p<0.001) in 2006. In patients older 
than 65 years the use of VKA increased from 7.3% to 12.8% in 
the same period (p<0.001). Pre-injury VKA use is age-related 
with a sharp increase between the age of 45 and 70 years. 
Head trauma patients on VKA have a higher risk of intracranial 
haemorrhage. The younger patients on anticoagulants have 
a 50% higher mortality [16]. Recent guidelines recommend 
emergency anticoagulation reversal with PCC and Vitamin K in 
trauma patients with major bleeding or cerebral haemorrhage 
who are on VKA treatment [17-19]. PCCs are classified 
into three-factor and four-factor products. Three-factor 
concentrates have therapeutically useful levels of FII, FIX and 
FX; four-factor PCCs contain FII, FVII, FIX, FX together with 
protein C and S. PCC is associated with a non negligible risk of 
thrombogenicity and disseminated intravascular coagulation 
(DIC) [20]. Eight retrospective studies have evaluated the 
outcomes associated with pre-injury anticoagulation therapy 
in patients admitted for traumatic head injury. In two of 
these studies the mortality was similar between the control 
and warfarin–treated patients; in the other six studies there 
was an increased mortality in the warfarin-treated group 
compare to the control group [21]. While mortality has been 
shown to increase in patients with traumatic brain injury on 
VKAs, data for trauma patients without brain injury are less 
Table 1. The Early Coagulation Support (ECS) Algorithm.
* 10 Units of PTL = 2 Units of single donor apheresis or 2 
Units of buffy coats pool PTL.
** 1 Plasma Unit = 250 mls of FFP or 200 mls of ; if Apheris 
plasma is used 1 Unit = 500 mls = 2 Units of FFP. 
Table 2. Early Goal Directed Therapy based on the results of 
thromboelastometry monitoring.
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clear. “Time to correction of the INR” or “extent of correction 
of the INR” have been used as a surrogate outcome of clinical 
effectiveness rather than the cessation of clinical bleeding or 
mortality. Only one retrospective analysis could demonstrate 
that in trauma patients receiving warfarin, the addition of 
PCC treatment to FFP and vitamin K results in a quicker INR 
reversal. However, no outcome improvement was observed 
[22]. Not withstanding the lack of strong evidence, the TUN 
experts agreed to introduce in the protocol the use of PCC 
for the emergency reversal of vitamin K dependent oral 
anticoagulation. Therefore, in patients with significant active 
bleeding known to be on VKAs, immediate administration 
of PCC (25 UI/Kg) is recommended even before INR results. 
PCC treatment will be subsequently adjusted according to 
INR results [23,24]. The F.C.S.A. recommendations [25] for the 
management of intracranial haemorrhage have been endorsed 
to guide treatment once INR is known (Table 3).
Recently several newer anticoagulants have been introduced 
in the clinical practice and a few more are under clinical 
development. Currently the oral thrombin inhibitor dabigatran 
etexilate (Pradaxa, Boehringer Ingelheim, Germany) is 
approved in the United States, Canada and Europe for the stoke 
prevention in atrial fibrillation and the oral factor Xa inhibitor 
rivaroxaban (Xareltro , Bayer AG, Germany) is approved for the 
prevention of venous thrombosis after orthopaedic surgery 
and for stroke prevention in atrial fibrillation.
These two drugs have a more balanced benefit/risk 
ratio and several advantages over warfarin: a rapid onset 
of action, a more predictable anticoagulant effect so that 
routine laboratory monitoring is not required, minor food 
and drugs interactions. Moreover they are expected to carry 
less hemorrhagic risks, particularly, less intracranial bleeding 
[26]. However a number of serious hemorrhages have been 
reported in the literature. On December 7, 2011, the FDA 
released a statement declaring that they were evaluating 
post-marketing reports of serious bleeding events in patients 
taking dabigatran, to determine if the rate of bleeding events 
was higher than what would be expected [27]. As novel 
agents, dabigatran and rivaroxaban, are relative unknown to 
the practicing community and there is little or no evidence 
to guide practical management when patients present with 
acute bleeding. Because of the short half-life of the newer 
agents observation and supportive care with immediate 
anticoagulant withdrawal is the preferred strategy in patients 
with minor or mechanically controlled bleeding. However 
when a life-threatening haemorrhage occurs, intervention 
with reversal agents might be warranted. Unfortunately 
neither plasma nor cryoprecipitate, are effective in reversing 
the anticoagulant effect of the new drugs [28]. A few studies 
have investigated reversal agents; all of these have used 
animal model or healthy human subjects to evaluate the 
role of different reversal drugs. The human studies focused 
on the effect of four-factor PCC on coagulation tests [29,30]
and demonstrated that high doses of 3-factors or 4-factors 
PCC are probably effective for the reversal of rivaroxaban, but 
not for dabigatran [31]. Dabigatran can be dialyzed, with the 
removal of about 60% of the drug over 2 to 3 hours, but data 
supporting this approach are limited and the potential use 
of dialysis in the context of severe trauma related bleeding 
is questionable [32]. The Italian Federation of Thrombosis 
Centres (FCSA) recently produced a consensus document 
suggesting the administration of 4-factors PCC for the reversal 
of rivaroxaban in the one shot dose of 50 UI/Kg [33].
Antiplatelet drugs - mostly aspirin and P2Y-thienopyridine 
antagonists (clopidogrel, prasugrel, ticlopidine) - are prescribed 
for prophylaxis and treatment in patients with cardiovascular 
or cerebrovascular diseases. These drugs are associated with 
an increased risk of intracranial haemorrhage. Drugs of both 
classes irreversibly inhibit platelets function making their 
short half-lives clinically irrelevant. For each day after the 
interruption of these medications, the 10-14% of normal 
platelet function is restored; so it takes 7 to 10 days for the 
entire platelet pool to be refurbished.
There is little evidence to guide platelet transfusion in major 
trauma patients on antiplatelet medications. A recent meta-
analysis of six studies failed to demonstrate any clear benefit 
of platelet transfusions in patients with either spontaneous 
or traumatic intracranial haemorrhage [34]. In a retrospective 
analysis of a cohort of 113 patients with traumatic intracerebral 
haemorrhage (TICH) on antiplatelet medications, Washington 
[35] et al., couldn’t find any statistically significant difference 
in outcome between patients treated with platelets and 
those who were not transfused. Similar data were reported by 
Downey in a retrospective study involving two level 1 Trauma 
Centres over a 4 years period [36]. Ivascu [37] and Fortuna 
[38] in two separate studies observed a non significant trend 
towards higher mortality in patients with traumatic brain injury 
treated with platelets transfusion, but patients transfused 
were older and presented a lower GCS and higher ISS [35]. 
All of these studies though, have some weakness: they are 
retrospective, relative small and the indication and timing 
for platelet transfusion were not standardized. The timing 
of transfusion might play a key role as the haematoma may 
set up very early after trauma [39].
Despite the lack of evidence supporting the use of platelets, 
Table 3. Anticoagulation reversal for bleeding patients on 
Vitamin K Antagonists (from FCSA recommendations 
[25], modified).
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many Institutions have implemented protocols for the reversal 
of platelet medications in the presence of TICH. According 
to a multidisciplinary Institutional protocol published by 
Campbell, [40] 5 Units of platelets concentrate should be 
transfused right on admission to the patients on ASA who 
present with a small TICH. Patients on clopidogrel or with 
large TICH should receive 10 Units of platelets together with 
0,3mcg/Kg of desmopressin. As patients with major trauma 
and critical bleeding often require surgical or intravascular 
procedures that may be significantly affected by platelet 
dysfunction, many Authors recommend the use of platelet 
concentrates even in the absence of brain injury [41]. The ECS 
protocol endorses this strategy, recommending platelets for 
patients on antiplatelet drugs with critical bleeding and/or 
intracranial haemorrhage and/or undergoing emergency 
surgery. In patients with TICH on ASA therapy, we suggest 
the administration of 1 apheresis platelet concentrate (single 
donor) or 1 pool platelet concentrate (from pooling of 4-6 
buffy coats). In patients with TICH or significant extracranial 
bleeding who are on ticlopidin, clopidogrel or dual antiplatelet 
drugs, we suggest the administration of 2 apheresis platelet 
concentrates or 2 pool platelet concentrates [42-44]. We 
also suggest to guide platelet transfusions with platelet 
function tests whereas available, if platelet dysfunction is 
documented [45].
Bleeding patients who are not on anticoagulants or 
antiplatelet drugs as well as those with ongoing bleeding in 
spite of a correct drug reversal, may need early coagulation 
support. Immediate identification of these cases is of 
paramount importance. Unfortunately clinical criteria as well 
as predictive scores have a lower than desirable predictive 
ability for massive transfusion. Predictive models of massive 
transfusion upon admission have been developed for this 
purpose. The Trauma Associated Severe Haemorrhage (TASH) 
score has been reported to have a high predictive value [46] 
and is widely used in Germany and other European countries. 
The TASH-score (Table 4) is based on a point-system taking 
into consideration clinical and laboratory data as well as 
the severity of injuries (orthopaedic fractures and intra-
abdominal fluid). In a multicenter study based on the data 
of the German Trauma Registry, Borgman [47] divided the 
population of trauma victims according to their TASH score. 
A TASH-score ≥ 15 was associated with a 40% risk to receive 
a massive transfusion. Patients with a TASH-score ≥ 15, had 
a high ISS (42±15,4), and a mortality rate of 39.5%. Patients 
of these groups who received a high plasma: PRBCs ratio 
had a significantly lower mortality than those who received 
a lower ratio, although the two groups were not different 
for other confounders. Patients with a TASH-score < 15 had 
a lower mortality (19.1%) which was not further reduced 
by the aggressive administration of plasma. With all the 
limitations of a retrospective study, these data suggest that 
trauma patients who carry at least a 40% risk of massive 
transfusion according to the TASH-score, may benefit from 
an aggressive treatment with a high plasma:PRBCs ratio. 
However, the timely identification of patients who need 
aggressive haemostatic resuscitation remains challenging. 
In recent papers, Maegele [48] and Brockamp [49] used the 
German Trauma Society database to evaluate the predictive 
values for massive transfusion (MT) of six different scoring 
algorithms. Although the weighted and more complex systems 
such as the TASH score had the highest overall accuracy, 
more simple score as the one proposed by Vandromme [50], 
performed nearly as well. The Vandromme-score is based on 
5 parameters four of which immediately available by clinical 
examination or by the generally available point of care devices: 
blood lactate ≥ 5 mmol/L, heart rate > 105 bpm, INR > 1.5, 
haemoglobin ≤ 11g/l and systolic blood pressure < 110 mm 
hg. Its predictive value for the need of massive transfusion 
increases with the number of positive parameters and the 
model with ≥ 3 positive criteria showed a sensitivity of 53% 
and a specificity of 98%. A major limitation of all models 
is their retrospective nature and the lack of prospective 
validation. It has been therefore suggested that individual 
triggers should be considered in order to improve the accuracy 
of the models [49]. An unpublished analysis of about 1700 
major-trauma cases from the Italian Trauma Registry (RIT) 
showed that hypotension (SBP ≤ 90) on hospital admission 
is associated with a mortality rate as high as 50% mainly due 
to uncontrolled haemorrhage. However many hypothensive 
patients do not meet the MT criteria as they do not survive 
enough time to receive 10 Units of PRBCs. On the base of the 
analysis of the literature and of the data of the TUN trauma 
registries, the panel of experts suggested to activate the 
ECS protocol whenever a significant uncontrolled bleeding 
is associated with one or more of the following criteria: SBP 
Variable Value Simplified score points
Hemoglobin (mg/dL) < 7 8
< 9 6
< 10 4
< 11 3
< 12 2
Intra abdominal free fluid +ve FAST 3
Orthopedic fractures Clinically unstable  
pelvic fracture
6
Femur fracture  
(open/dislocated)
3
Base excess < - 10 4
<  - 6 3
<  - 2 1
Systolic blood pressure (mm Hg) < 100 4
< 120 1
Heart rate (beat/min) ≥ 120 2
Sex Male 1
Table 4. The TASH-score (from Yűcel N et al. J Trauma 2006).
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< 100, BE < -6, Lactate > 5mmol/L, Haemoglobin < 9gr/dL or 
a INR > 1,5. The last criterion may be relevant in the case of 
patients referred from other hospitals with laboratory data 
showing an impaired coagulation. All these patients are 
expected to be transfused with universal blood soon after 
admission. Four Units of universal PRBCs is the standard 
package for emergency transfusion immediately available 
in the trauma bay of the TUN trauma centres.
The utility of the standard coagulation tests (eg., 
prothrombin time [PT], international normalized ratio 
[INR], activated partial tromboplastin time [aPTT], platelets 
count and fibrinogen [Clauss method]) to guide the acute 
haemostatic treatment in trauma patients with significant 
bleeding is limited. First, their results are inevitably delayed. 
In addition, because they are not performed on whole blood 
but on plasma, they cannot analyze the entire process of 
coagulation as it occurs in vivo. Moreover hyperfibrinolysis 
cannot be detected [51]. Rotational thromboelastometry 
(ROTEM) and thromboelastography (TEG) offer a quicker 
and more complete monitoring and allow a goal directed 
therapy. ROTEM, better than TEG, can also quickly detect 
fibrinolysis. Although the clear evidence of a positive impact 
on patients outcome is still missing, viscoelastic tests allow 
to distinguish the different haemostatic disorders following 
trauma, facilitating the proper management. The early use of 
thromboelastometry to guide treatment is recommended by 
the Austrian Guidelines [12]. As ROTEM or TEG are not always 
available at the moment in many Italian hospitals, the ECS 
protocol has been conceived without the obligatory guide 
of viscoelastic monitoring. However the panel acknowledges 
that viscoelastic monitoring may significantly improve the 
efficacy of the ECS protocol.
Brohi et al., recently observed that as many as 41% of the 
hypotensive trauma patients have fibrinogen level below 
1.5g/L on hospital admission and its reduction is associated 
with the increasing base deficit [3]. A high percentage of the 
patients who meet the ECS criteria are therefore expected 
to have a low fibrinogen. According to the ECS protocol as 
soon as these patients start the transfusion with universal 
PRBCs they should receive an initial dose of 2 gr of fibrinogen 
concentrate. In the Brohi’s study patients who did not receive 
any source of fibrinogen had a reduction in fibrinogen level to 
1.2g/L (1.0-1.8) as an average after the first 4 Units of PRBCs. 
The standard dose of 2 gr of fibrinogen concentrate therefore 
aims to immediately provide the needed amount of fibrinogen 
to prevent its expected decrease following the first 4 Units of 
PRBCs [3]. Two grams of fibrinogen is approximately equal to 
the content of 4 plasma (250ml) Units. In a recent multicenter 
study in cardiac surgery Görlinger [53] demonstrated that a 
goal-directed therapy with fibrinogen concentrate and Point-of 
Care viscoelastic monitoring, was associated with a threefold 
reduction of intraoperative massive transfusion and a 90% 
reduction in the use of plasma. Although massive bleeding in 
trauma patients may have different underlying mechanisms 
than intra-operative bleeding, reducing the time to achieve 
effective coagulation support should be equally important. 
Fibrinogen plays a key role in clot formation and clot firmness 
because it is the final substrate of coagulation and the ligand 
of the platelet GPIIb/IIIa receptors. Restoring or increasing 
fibrinogen levels may significantly contribute to improve 
the clotting process, control the bleeding and reduce the 
amount of transfused blood and plasma. In his retrospective 
study Schöchl showed that ROTEM guided haemostatic 
therapy with fibrinogen concentrate, was associated with 
a significant reduction in the number of patients requiring 
platelet transfusion and RBC transfusion, as compared with 
conventional treatment with plasma. However patients in 
both group required only 6 PRBCs Units as an average, thus 
the majority of them did not meet the MT definition. In 
truth Schöchl demonstrated that early coagulation support 
may effectively reduce the exposure of the bleeding trauma 
patients to allogeneic blood products, which is one of the 
goals of the ECS protocol.
In the daily practice of the TUN Trauma Centres a significant 
number of patients who eventually require less than 6 Units 
of PRBCs, receive plasma transfusion. Plasma is ordered in 
a fixed 1:1 ratio with PRBCs, immediately on arrival at the 
Emergency Room and immediately thawed in order to shorten 
the time-to treat. Fibrinogen concentrate may allow a little 
delay in the decision to thaw the plasma possibly reducing 
the waste of thawed plasma or inappropriate transfusion. 
Transfusion of plasma and platelets is independently associated 
with the development of multiple organ failure in critically 
injured patients. In a retrospective study on a large number 
of transfused patients requiring less than 10 Units of PRBC 
within 12 hours of admission, Inaba [9] observed a higher rate 
of complication in the patients receiving plasma. Patients 
receiving more than 6 Units of plasma had a 12-fold increase 
in ARDS, 6-fold increase in MODS and 4-fold increase in 
pneumonia and sepsis with non significant improvement 
in survival. Johnson [11] confirmed these findings, but 
demonstrated that the deleterious effect associated with 
plasma transfusion outweighed the survival benefits of 
plasma only among patients receiving fewer than 6 Units 
of blood (PRBC). Therefore avoiding plasma transfusion in 
trauma patients who will not require at least 6 Units of PRBCs 
might be beneficial.
However fibrinogen concentrate does not provide volume 
expansion, hence higher amounts of crystalloids and/or 
colloids need to be infused to replace volume if a “plasma 
free” strategy is adopted. Crystalloids and more importantly, 
colloids significantly impair the clotting process, either by 
diluting clotting factors or directly impairing the clot strength. 
The potentially greater fluid infusion when concentrates are 
employed instead of plasma, may hamper the efficacy of this 
treatment strategy. This may explain the reason why, even 
in Schöchl series, a percentage of the bleeding patients still 
receive plasma. As no proper study have compared yet the 
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“factor based” strategy with the “plasma based” approach this 
issue hasn’t been settled. The rationale of the TUN protocol 
strategy is to provide a rapid support to the clotting process 
by the early administration of fibrinogen concentrate, with 
the aim to reduce plasma transfusion at least in patients who 
eventually will not need massive transfusion. These patients 
are the ones expected to get more harm than benefits from 
plasma.
Patients who continue to present significant a bleeding not 
withstanding early coagulation support and damage control 
surgery, will usually require more than 10 Units of PRBCs and 
meet the definition of massive transfusion (MT). Although data 
in the literature consistently show that early and aggressive 
plasma transfusion improve the survival of these patients, the 
optimal FFP/PRBC and PLT/PRBC ratio is controversial because 
of the possible survival bias flawing most studies [54,55]. A 
recent multicenter prospective study on a large population 
of patients undergoing MT showed that high FFP/PRBC and 
PLT/PRBC ratios are associated with a survival benefit also 
when time-dependency is accounted for [56]. 
The TUN expert committee feels there are still no enough 
evidence in the literature to adopt a “plasma free” strategy 
for the patients who require massive transfusion, for the 
following reasons: The pathophysiology of TIC is not yet [57] 
fully understood. Early coagulopathy (EC) occurring before 
hospital admission is caused mainly by tissue hypoperfusion 
and severe tissue injury. EC might have different causes than 
coagulopathy associated with haemodiluition, acidosis and 
hypothermia. Patients with tissue hypoperfusion and severe 
tissue damage have a strong activation of the protein C 
pathway that seems to be associated with a depletion in PC 
levels and protein C stores. This brings to increased levels 
of plasminogen activator inhibitor-1, favouring fibrinolyisis. 
Activated protein C also inactivates factor Va and factor VIIIa 
[58] bringing to a significant consumption of factor V and 
VIII. Coagulopathy caused by hypoperfusion is therefore 
characterized by an acquired deficit in coagulation factor V 
(and by a less extent, VIII,VII,II,IX,X and XI [59]) together with 
a hyperfibrinolytic condition. Acidosis as a consequence 
of massive haemorrhage has a detrimental effect on the 
coagulation cascade; a low pH strongly affects the activity 
of factor VII and to a lesser extent factor X and factor V [60]. 
Moreover massive bleeding may cause also an acquired deficit 
of factor XIII which has an important role in clot stabilization 
and clot firmness. It has been suggested that a decreased 
factor V activity as well as a deficit in factor XIII concentration 
might play a role in the pathogenesis of the early onset acute 
traumatic coagulopathy [61,62]. Unfortunately factor XIII is 
available in some European country, but not in Italy. Some 
concern therefore has been raised about the potential risk of 
a “plasma free” strategy, as administration of plasma might 
play a role in restoring factor XIII levels and factor V activity 
in the coagulopathic patients with severe hypoperfusion. It 
has been remarked that a level of factor V as low as 5% still 
allows an effective coagulation in patients with hematologic 
diseases; however bleeding trauma patients might require 
higher levels.
In case of massive bleeding the restriction of plasma 
implies higher quantities of crystalloids and colloids for 
volume replacement. High volume of crystalloids may 
affect the haemostatic process through factors dilution and 
hypercloremic acidosis. The use of colloids has also been 
recently challenged as they cause fibrinogen dysfunction 
reducing the clot stability. In a recent randomized controlled 
study comparing saline with HES 130/0.4 for trauma 
resuscitation, patients in the HES group required significantly 
more blood and blood products [63]. Moreover it has been 
shown that the use of HES for fluid resuscitation is associated 
with a significantly higher complication rate if compared 
with normal saline [64]. Therefore volume replacement with 
colloids should probably be limited if not abandoned.
The panel agreed that additional data from controlled 
trials are needed before a pure “plasma free strategy” can 
be endorsed in the ECS protocol even for the patients 
requiring MT. If a viscoelastic monitoring is available, the 
ECS protocol recommend to treat the patients who need 
MT with the administration of plasma with the addition of 
factors, following the goal-directed algorithm presented in 
Table 2. Treatment goals has been adapted from the AUVA 
Protocol [65] which is based on rotational thromboelastometry 
(ROTEM). Thromboelastography (TEG) might provide the same 
information. A treatment algorithm for TEG guided treatment 
has been proposed by Johansson et al., [66]. If ROTEM and TEG 
are not available , the ECS protocol recommends a standardized 
approach aimed to transfuse blood and plasma keeping the 
plasma/PRBCs ratio ≥ 1.5 and to maintain platelets over 100.000.
The economic impact of the ECS protocol has been one 
of the main concerns addressed by the panellists. Data from 
the Surgical and Trauma Intensive Care Units of the Insbruck 
University show that a goal directed coagulation management 
based on Point of Care monitoring and the use of factors 
brought to a sharp reduction in plasma transfusions (-88%) 
and PRBCs requirement over a 5 years period [53]. The overall 
cost of blood products decreased by 200.000 Euro per year in 
spite of a significant increase in the cost of fibrinogen. However 
these results are referred to the general population of patients 
requiring transfusions, including patients undergoing elective 
cardiac surgery, therefore they might not be applicable to 
major bleeding in trauma victims. Fibrinogen concentrate is 
imported in Italy in limited amount provided authorization 
by the National Agency AIFA. One gram of fibrinogen costs 
around 400 Euro, thus the first step of the ECS protocol is 
associated with an estimated cost for fibrinogen concentrate 
of 800 Euros. The equivalent cost if plasma was used as the 
source of fibrinogen is difficult to calculate, because the 
cost of blood collection from blood donors cannot be easily 
quantified. However one Unit (200 mls) of industrial purified 
plasma, costs around 75 Euro. Therefore the estimated cost 
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of 1000 mls of commercial plasma, with a content of 2 g 
of fibrinogen, is 375 Euro. The additional cost of the TUN 
protocol strategy to reduce plasma transfusion in patients who 
eventually will not need massive transfusion have therefore 
been estimated in 425 Euro per patient. These patients are the 
ones expected to get more harm than benefits from plasma 
and the additional treatment cost should be balanced by the 
expected reduction in plasma related complications, ICU and 
hospital length of stay. The impact of the ECS protocol on the 
global treatment cost in case of massive transfusion, is even 
more complex to estimate also because an earlier support to 
the clotting process may reduce transfusion requirements as 
shown by Görlinger [53]. The TUN trauma centers that adopt 
the protocol will therefore carefully monitor financial aspects.
Conclusion
To meet the need of standardized the treatment of trauma 
patients with critical bleeding, the Italian trauma centers of the 
TUN network have developed a common therapeutic protocol 
called ECS. The protocol aims to avoid the use of plasma in 
the patients who will need a limited number of PRBCs, reduce 
the plasma related complications, and improve coagulation 
support in patients requiring massive transfusion through 
the early restoration of fibrinogen blood concentration. The 
ECS protocol has been developed assuming to have a point 
of care monitoring of coagulation, but can also be applied 
if a viscoelastic monitoring is not available. The ECS will be 
adopted by the TUN trauma centers with strict monitoring of 
economic impact and clinical results.
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